Use of alpha-21 selective adrenergic receptor agonists in...

Details Use of alpha-21 selective adrenergic receptor agonists in... Use of alpha-21 selective adrenergic receptor agonists in...

A - Human Necessities

61

K

167/271

A61K 31/165 (2006.01) A61K 31/155 (2006.01)

Patent

CA 1307741

ABSTRACT OF THE DISCLOSURE Disclosed is a composition for treating memory disorders and cognitive decline, e.g., age-related cognitive decline, in a primate which includes a therapeutically effective amount of an alpha-2 agonist having a high affinity for the alpha-2I subtype, e.g., guanfacine and guanabenz or a nontoxic, pharmaceutically acceptable salt thereof. Particularly preferred is the use of alpha-2I selective agonists such as guanfacine.

551279

Affiliated with

Also associated with

Rating

Use of alpha-21 selective adrenergic receptor agonists in... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of alpha-21 selective adrenergic receptor agonists in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of alpha-21 selective adrenergic receptor agonists in... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1216294